Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?

• Main Authors: Maamar Kara (Author), Omar Aitmokhtar (Author), Adel Azaza (Author), Saber Seddiki (Author), Faiza Harbi (Author), Arezki Sik (Author), Kheireddine Merad (Author), Salim Benkhedda (Author)
• Format: Book
• Published: Archives of Hematology Case Reports and Reviews - Peertechz Publications, 2016-12-30.
• Subjects: Editorial
• Online Access: Connect to this object online.

Summary

<p>ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: InternationalNormalized Ratio; MI: Myocardial Infarction; PCI: Percutaneous Coronary Intervention; PIONEER AF-PCI: Open-Label, Randomized, Controlled, Multicenterstudy Exploring two Treatment Strategiesof Rivaroxaban and a Dose-Adjusted Oral Vitamink Antagonist Treatment Strategy in Subjectswith Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention; TIMI: Thrombolysis In Myocardial Infarction; VKA: Vitamin K Antagonist</p><p>Approximately 15% of AF patients have a history of myocardial infarction. Between 5-15% of them will require stenting at some point in their lives with the need for a triple therapy combining an oral anticoagulant, a P2Y12 Inhibitor and aspirin [1-3]. This combination requires careful evaluation of bleeding risk, stroke risk and the risk of acute coronary syndromes (ACS) to reduce the risk of major hemorrhage [4-6]. In this context, the PIONEER AF-PCI [7], trial was conducted to evaluate the effectiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents.<br></p>

DOI

10.17352/ahcrr.000003